JP2002523508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002523508A5 JP2002523508A5 JP2000567532A JP2000567532A JP2002523508A5 JP 2002523508 A5 JP2002523508 A5 JP 2002523508A5 JP 2000567532 A JP2000567532 A JP 2000567532A JP 2000567532 A JP2000567532 A JP 2000567532A JP 2002523508 A5 JP2002523508 A5 JP 2002523508A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- hydrogen
- disorder
- formula
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 29
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 239000001257 hydrogen Substances 0.000 description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- -1 arylsulfoxyl Chemical group 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- AYNAVHUTXWVDLR-UHFFFAOYSA-N 1-(6,7-difluoro-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl)propan-2-amine Chemical compound C12=CC(F)=C(F)C=C2C(CC(N)C)=C2N1CCC2 AYNAVHUTXWVDLR-UHFFFAOYSA-N 0.000 description 1
- VCCGTYYMZYICBO-UHFFFAOYSA-N 1-(6-bromo-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl)propan-2-amine Chemical compound C12=CC=C(Br)C=C2C(CC(N)C)=C2N1CCC2 VCCGTYYMZYICBO-UHFFFAOYSA-N 0.000 description 1
- XNFYXIJQNZVXAX-UHFFFAOYSA-N 1-(6-chloro-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl)propan-2-amine Chemical compound C12=CC=C(Cl)C=C2C(CC(N)C)=C2N1CCC2 XNFYXIJQNZVXAX-UHFFFAOYSA-N 0.000 description 1
- SPMDNODKUUODIS-UHFFFAOYSA-N 1-(6-methylsulfanyl-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl)propan-2-amine Chemical compound CSC1=CC=C2N(CCC3)C3=C(CC(C)N)C2=C1 SPMDNODKUUODIS-UHFFFAOYSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000027626 Neurocognitive disease Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 208000025748 atypical depressive disease Diseases 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- 125000005202 dialkylaminocarbonyloxy group Chemical group 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9819035.8A GB9819035D0 (en) | 1998-09-01 | 1998-09-01 | Chemical compounds VII |
| GB9819035.8 | 1998-09-01 | ||
| PCT/GB1999/002884 WO2000012510A1 (en) | 1998-09-01 | 1999-09-01 | Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002523508A JP2002523508A (ja) | 2002-07-30 |
| JP2002523508A5 true JP2002523508A5 (enExample) | 2006-10-26 |
Family
ID=10838167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000567532A Pending JP2002523508A (ja) | 1998-09-01 | 1999-09-01 | ５−ｈｔ２ｃアゴニストとしての、ピロロインドール、ピリドインドールおよびアゼピノインドール |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6433175B1 (enExample) |
| EP (1) | EP1109813B1 (enExample) |
| JP (1) | JP2002523508A (enExample) |
| KR (2) | KR20070062609A (enExample) |
| CN (1) | CN1165537C (enExample) |
| AT (1) | ATE273308T1 (enExample) |
| AU (1) | AU758084B2 (enExample) |
| BR (1) | BR9913477A (enExample) |
| CA (1) | CA2341991C (enExample) |
| CZ (1) | CZ296275B6 (enExample) |
| DE (1) | DE69919364T2 (enExample) |
| DK (1) | DK1109813T3 (enExample) |
| ES (1) | ES2226430T3 (enExample) |
| GB (1) | GB9819035D0 (enExample) |
| HR (1) | HRP20010126B1 (enExample) |
| HU (1) | HUP0103333A3 (enExample) |
| ID (1) | ID28842A (enExample) |
| IL (2) | IL141659A0 (enExample) |
| MX (1) | MXPA01002101A (enExample) |
| NO (1) | NO321527B1 (enExample) |
| NZ (1) | NZ510097A (enExample) |
| PL (1) | PL346427A1 (enExample) |
| PT (1) | PT1109813E (enExample) |
| RU (1) | RU2232162C2 (enExample) |
| SI (1) | SI1109813T1 (enExample) |
| TR (2) | TR200501110T2 (enExample) |
| WO (1) | WO2000012510A1 (enExample) |
| YU (1) | YU16001A (enExample) |
| ZA (1) | ZA200101457B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960579B1 (en) | 1998-05-19 | 2005-11-01 | Alcon Manufacturing, Ltd. | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders |
| GB9902047D0 (en) * | 1999-01-29 | 1999-03-17 | Cerebrus Ltd | Chemical compounds XI |
| US6465467B1 (en) | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
| GB9918965D0 (en) * | 1999-08-11 | 1999-10-13 | Cerebrus Ltd | Chemical compounds xxi |
| SE0002754D0 (sv) * | 2000-07-21 | 2000-07-21 | Pharmacia & Upjohn Ab | New pharmaceutical combination formulation and method of treatment with the combination |
| US6818639B2 (en) | 2000-07-21 | 2004-11-16 | Biovitrum Ab | Pharmaceutical combination formulation and method of treatment with the combination |
| JP4204315B2 (ja) | 2000-11-20 | 2009-01-07 | ビオヴィトルム・アクチボラゲット（プブリクト） | セロトニン５−ｈｔ２レセプターのアンタゴニストとしてのピペラジニルピラジン化合物 |
| SE0004245D0 (sv) | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
| HUP0303316A2 (hu) | 2000-12-20 | 2004-01-28 | Bristol-Myers Squibb Pharma Company | Aril- és amino-aril-szubsztituált szerotoninreceptor agonista és antagonista ligandumok és ezeket tartalmazó gyógyszerkészítmények |
| BR0116605A (pt) * | 2000-12-27 | 2003-09-30 | Hoffmann La Roche | Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono |
| AU2002259312B2 (en) | 2001-06-01 | 2007-01-04 | Alcon, Inc. | Novel arylaminopropane analogues and their use for the treatment of glaucoma |
| CA2447156A1 (en) | 2001-06-01 | 2002-12-12 | Alcon, Inc. | Novel fused indazoles and indoles and their use for the treatment of glaucoma |
| ATE318821T1 (de) | 2001-06-01 | 2006-03-15 | Alcon Inc | Pyranoindazole und ihre verwendung in der glaukombehandlung |
| TW593302B (en) | 2001-12-20 | 2004-06-21 | Alcon Inc | Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma |
| BR0311970A (pt) | 2002-06-19 | 2005-03-29 | Biovitrum Ab | Novos compostos, seu uso e preparação |
| JP2006501245A (ja) * | 2002-08-30 | 2006-01-12 | アルコン，インコーポレイテッド | 置換された５−クロマン−５−イル−エチルアミン化合物および緑内障の治療のためのその使用 |
| BR0316775A (pt) | 2002-12-13 | 2005-11-01 | Alcon Inc | Novos análogos de benzopirano e seu uso para o tratamento de glaucoma |
| CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
| GB0314967D0 (en) * | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
| US7435837B2 (en) * | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| US7476687B2 (en) | 2003-11-26 | 2009-01-13 | Alcon, Inc. | Substituted furo[2,3-g]indazoles for the treatment of glaucoma |
| US7338972B1 (en) | 2003-12-15 | 2008-03-04 | Alcon, Inc. | Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma |
| AR046890A1 (es) | 2003-12-15 | 2005-12-28 | Alcon Inc | [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma. |
| US7129257B1 (en) | 2003-12-15 | 2006-10-31 | Alcon, Inc. | Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma |
| JP5173190B2 (ja) | 2004-08-25 | 2013-03-27 | 武田薬品工業株式会社 | 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法 |
| BRPI0517955A (pt) | 2004-11-01 | 2008-10-21 | Wyeth Corp | indolizinas substituìdas e derivados como agentes de snc |
| WO2006062839A1 (en) | 2004-12-08 | 2006-06-15 | Alcon, Inc. | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma |
| NZ560917A (en) | 2005-03-31 | 2011-01-28 | Pfizer Prod Inc | Cyclopentapyridine and tetrahydroquinoline derivatives |
| FR2884252B1 (fr) * | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90 |
| EP1879875A1 (en) * | 2005-04-22 | 2008-01-23 | Wyeth | Crystal forms opf {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride |
| CA2609634C (en) * | 2005-05-03 | 2011-02-01 | F. Hoffmann-La Roche Ag | Tetracyclic azapyrazinoindolines as 5-ht2 ligands |
| JP5528699B2 (ja) | 2006-05-16 | 2014-06-25 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
| ATE496894T1 (de) * | 2006-07-14 | 2011-02-15 | Pfizer Prod Inc | Tartratsalz von (7s)-7-ä(5-fluor-2- |
| JP5520051B2 (ja) | 2007-11-15 | 2014-06-11 | 武田薬品工業株式会社 | 縮合ピリジン誘導体およびその用途 |
| KR101062376B1 (ko) | 2008-04-10 | 2011-09-06 | 한국화학연구원 | 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물 |
| WO2011071136A1 (ja) | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| CN102964352B (zh) * | 2012-11-23 | 2015-04-08 | 华中师范大学 | 具有生物活性的手性2,3-二氢吡咯[1,2-a]吲哚衍生物及其不对称合成方法 |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| WO2019131902A1 (ja) | 2017-12-27 | 2019-07-04 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
| WO2020072675A1 (en) | 2018-10-02 | 2020-04-09 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2c (5-ht2c) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3250783A (en) * | 1964-09-21 | 1966-05-10 | American Cyanamid Co | Novel pyrrolo (1, 2-alpha) indoles |
| US4134894A (en) * | 1978-05-04 | 1979-01-16 | Warner-Lambert Company | Pyrrolo[1,2-a]indole compounds |
| GB8416724D0 (en) * | 1984-06-30 | 1984-08-01 | Sorbio Sa Lab | Active compounds |
| US4778812A (en) * | 1987-06-12 | 1988-10-18 | American Home Products Corporation | 2,3-dihydro-9-methyl-1H-pyrrolo[1,2-a]indol-1-amines and derivatives thereof |
| GB8802127D0 (en) * | 1988-02-01 | 1988-03-02 | Glaxo Group Ltd | Chemical compounds |
| MC2096A1 (fr) * | 1989-02-23 | 1991-02-15 | Hoffmann La Roche | Pyrroles substitues |
| RU2104279C1 (ru) * | 1992-03-12 | 1998-02-10 | Смитклайн Бичам Плс | Конденсированное индольное производное или его фармацевтически приемлемая соль, фармацевтическая композиция, проявляющая активность антагониста 5-нт*004-рецептора |
| EP0572863A1 (de) * | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | ZNS Pyrazinoindole |
| TW251284B (enExample) * | 1992-11-02 | 1995-07-11 | Pfizer | |
| EP0688216A1 (en) * | 1993-03-08 | 1995-12-27 | Fujisawa Pharmaceutical Co., Ltd. | Medicament for treating or preventing cerebrovascular diseases |
| US5629427A (en) * | 1993-08-26 | 1997-05-13 | Peterson; Dwight M. | 2,7-diaminomitosene analogues |
-
1998
- 1998-09-01 GB GBGB9819035.8A patent/GB9819035D0/en not_active Ceased
-
1999
- 1999-09-01 ES ES99943091T patent/ES2226430T3/es not_active Expired - Lifetime
- 1999-09-01 AU AU56375/99A patent/AU758084B2/en not_active Ceased
- 1999-09-01 ID IDW20010677A patent/ID28842A/id unknown
- 1999-09-01 JP JP2000567532A patent/JP2002523508A/ja active Pending
- 1999-09-01 KR KR1020077011961A patent/KR20070062609A/ko not_active Abandoned
- 1999-09-01 HR HR20010126A patent/HRP20010126B1/xx not_active IP Right Cessation
- 1999-09-01 CA CA002341991A patent/CA2341991C/en not_active Expired - Fee Related
- 1999-09-01 NZ NZ510097A patent/NZ510097A/xx unknown
- 1999-09-01 US US09/763,889 patent/US6433175B1/en not_active Expired - Fee Related
- 1999-09-01 SI SI9930677T patent/SI1109813T1/xx unknown
- 1999-09-01 TR TR2005/01110T patent/TR200501110T2/xx unknown
- 1999-09-01 TR TR2001/00659T patent/TR200100659T2/xx unknown
- 1999-09-01 IL IL14165999A patent/IL141659A0/xx active IP Right Grant
- 1999-09-01 HU HU0103333A patent/HUP0103333A3/hu unknown
- 1999-09-01 MX MXPA01002101A patent/MXPA01002101A/es not_active IP Right Cessation
- 1999-09-01 PT PT99943091T patent/PT1109813E/pt unknown
- 1999-09-01 BR BR9913477-2A patent/BR9913477A/pt not_active Application Discontinuation
- 1999-09-01 PL PL99346427A patent/PL346427A1/xx not_active IP Right Cessation
- 1999-09-01 RU RU2001108570/04A patent/RU2232162C2/ru not_active IP Right Cessation
- 1999-09-01 KR KR1020017002608A patent/KR100768595B1/ko not_active Expired - Fee Related
- 1999-09-01 WO PCT/GB1999/002884 patent/WO2000012510A1/en not_active Ceased
- 1999-09-01 AT AT99943091T patent/ATE273308T1/de not_active IP Right Cessation
- 1999-09-01 CN CNB998128341A patent/CN1165537C/zh not_active Expired - Fee Related
- 1999-09-01 YU YU16001A patent/YU16001A/sh unknown
- 1999-09-01 CZ CZ20010772A patent/CZ296275B6/cs not_active IP Right Cessation
- 1999-09-01 DE DE69919364T patent/DE69919364T2/de not_active Expired - Fee Related
- 1999-09-01 DK DK99943091T patent/DK1109813T3/da active
- 1999-09-01 EP EP99943091A patent/EP1109813B1/en not_active Expired - Lifetime
-
2001
- 2001-02-21 ZA ZA200101457A patent/ZA200101457B/xx unknown
- 2001-02-26 IL IL141659A patent/IL141659A/en not_active IP Right Cessation
- 2001-02-27 NO NO20010991A patent/NO321527B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002523491A5 (enExample) | ||
| JP2002523506A5 (enExample) | ||
| JP2003507367A5 (enExample) | ||
| RU2001108570A (ru) | Пирролоиндолы, пиридиноиндолы и азепиноиндолы в качестве агонистов 5-нт2с | |
| JP2002535408A5 (enExample) | ||
| JP2002525280A5 (enExample) | ||
| JP2003507366A5 (enExample) | ||
| JP2005527579A5 (enExample) | ||
| BR122017023795B8 (pt) | método para preparação de composição farmacêutica | |
| JP2004527467A5 (enExample) | ||
| CA2529320A1 (en) | Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases | |
| RU2018130727A (ru) | Органические соединения | |
| JP2007508361A5 (enExample) | ||
| JP2007516941A5 (enExample) | ||
| JP2004532823A5 (enExample) | ||
| CA2514267A1 (en) | Malonamide derivatives as gamma-secretase inhibitors | |
| EA200800430A1 (ru) | Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов | |
| CA2702482A1 (en) | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | |
| MX2009005509A (es) | 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a). | |
| MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
| WO2004089308A3 (en) | Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5 | |
| WO2006019886A3 (en) | Pyrrolo(oxo)isoquinolines as 5ht ligands | |
| WO2006067428A3 (en) | 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands | |
| CN101460484A (zh) | 6-甲氧基-8-[4-(1-(5-氟)-喹啉-8-基-哌啶-4-基)-哌嗪-1-基]-喹啉盐酸盐 | |
| TW200613255A (en) | Therapeutic diphenyl ether ligands |